These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 3486623)

  • 21. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts.
    Chizzolini C; Rezzonico R; Ribbens C; Burger D; Wollheim FA; Dayer JM
    Arthritis Rheum; 1998 Nov; 41(11):2039-47. PubMed ID: 9811060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of L-5-hydroxytryptophan in autistic children.
    Sverd J; Kupietz SS; Winsberg BG; Hurwic MJ; Becker L
    J Autism Child Schizophr; 1978 Jun; 8(2):171-80. PubMed ID: 307546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential regulatory elements of the constitutive up-regulated alpha2(I) collagen gene in scleroderma dermal fibroblasts.
    Jinnin M; Ihn H; Mimura Y; Asano Y; Tamaki K
    Biochem Biophys Res Commun; 2006 May; 343(3):904-9. PubMed ID: 16564026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin.
    Louneva N; Huaman G; Fertala J; Jiménez SA
    Arthritis Rheum; 2006 Apr; 54(4):1298-308. PubMed ID: 16575855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Ultrastructural comparative study of the behavior of collagen tissue and elastic tissue during 3 pathological states (Marfans disease, scleroderma due to vitamin K-1 lathyrogenic effect of penicillamine)].
    Gauthier Y; Surlève-Bazeille JE; Gauthier O; Texier L
    Ann Dermatol Syphiligr (Paris); 1973; 100(5-6):525-9. PubMed ID: 4802994
    [No Abstract]   [Full Text] [Related]  

  • 26. Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts.
    Asano Y; Ihn H; Yamane K; Jinnin M; Mimura Y; Tamaki K
    Arthritis Rheum; 2005 Apr; 52(4):1237-47. PubMed ID: 15818662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture.
    Whiteside TL; Buckingham RB; Prince RK; Rodnan GP
    J Lab Clin Med; 1984 Sep; 104(3):355-69. PubMed ID: 6088655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
    Wang Y; Fan PS; Kahaleh B
    Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How physician obesity specialists use drugs to treat obesity.
    Hendricks EJ; Rothman RB; Greenway FL
    Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts.
    Murota H; Hamasaki Y; Nakashima T; Yamamoto K; Katayama I; Matsuyama T
    Arthritis Rheum; 2003 Apr; 48(4):1117-25. PubMed ID: 12687556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basic fibroblast growth factor inhibits basal and transforming growth factor-beta induced collagen alpha 2(I) gene expression in scleroderma and normal fibroblasts.
    Ichiki Y; Smith EA; LeRoy EC; Trojanowska M
    J Rheumatol; 1997 Jan; 24(1):90-5. PubMed ID: 9002017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Down-regulation of TGF-beta1-induced type I collagen synthesis by AP-1 transcription factor decoy in scleroderma fibroblasts.
    Cho JW; Kim JY; Kim CW; Lee KS
    J Dermatol Sci; 2006 Sep; 43(3):207-9. PubMed ID: 16790335
    [No Abstract]   [Full Text] [Related]  

  • 33. Letters: Fibroblasts from a patient with scleroderma reveal abnormal metabolism.
    Krieg T; Müller PK; Goerz G
    Arch Dermatol Res (1975); 1977 Jul; 259(1):105-7. PubMed ID: 900987
    [No Abstract]   [Full Text] [Related]  

  • 34. L-5-hydroxytryptophan in the treatment of anxiety disorders.
    Kahn RS; Westenberg HG
    J Affect Disord; 1985; 8(2):197-200. PubMed ID: 3157732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myoclonus in the young after 5-hydroxytryptophan.
    Coleman M
    N Engl J Med; 1977 Apr; 296(14):820. PubMed ID: 138798
    [No Abstract]   [Full Text] [Related]  

  • 36. [Sclerodermiform and poikilodermic syndrome during treatment with carbidopa and 5-hydroxytryptophan. Culture of fibroblasts with biochemical analysis of collagen metabolism].
    Chamson A; Périer C; Frey J
    Ann Dermatol Venereol; 1986; 113(1):71. PubMed ID: 3486623
    [No Abstract]   [Full Text] [Related]  

  • 37. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Sternberg EM; Van Woert MH; Young SN; Magnussen I; Baker H; Gauthier S; Osterland CK
    N Engl J Med; 1980 Oct; 303(14):782-7. PubMed ID: 6997735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-related scleroderma-like illness. The Fine page.
    Fine RM
    Int J Dermatol; 1981 Jun; 20(5):354. PubMed ID: 6972361
    [No Abstract]   [Full Text] [Related]  

  • 39. Toxic oil syndrome (Spanish oil disease) and chemically induced scleroderma-like conditions.
    Rush PJ; Bell MJ; Fam AG
    J Rheumatol; 1984 Jun; 11(3):262-4. PubMed ID: 6204046
    [No Abstract]   [Full Text] [Related]  

  • 40. [Scleroderma-like syndrome with bullous morphea during treatment with 5-hydroxytryptophan, carbidopa and flunitrazepam].
    Lampert A; Joly P; Thomine E; Ortoli JC; Lauret P
    Ann Dermatol Venereol; 1992; 119(3):209-11. PubMed ID: 1605525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.